Indivior PLC (NASDAQ:INDV) Receives Average Recommendation of “Buy” from Brokerages

Indivior PLC (NASDAQ:INDV) has been assigned a consensus recommendation of “Buy” from the seven research firms that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation, five have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $22.00.

Several analysts recently issued reports on INDV shares. Jefferies Financial Group initiated coverage on Indivior in a report on Tuesday, July 22nd. They issued a “buy” rating and a $20.00 price target on the stock. HC Wainwright initiated coverage on Indivior in a research note on Wednesday, August 6th. They set a “buy” rating and a $27.00 target price on the stock. Craig Hallum lifted their target price on Indivior from $27.00 to $34.00 and gave the company a “buy” rating in a research note on Wednesday, August 27th. Wall Street Zen raised Indivior from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 21st. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Indivior in a research note on Saturday, September 27th.

Institutional Trading of Indivior

Several hedge funds have recently added to or reduced their stakes in INDV. Hennion & Walsh Asset Management Inc. raised its stake in Indivior by 48.5% during the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 142,444 shares of the company’s stock valued at $1,357,000 after acquiring an additional 46,509 shares in the last quarter. Schaper Benz & Wise Investment Counsel Inc. WI bought a new stake in shares of Indivior in the 1st quarter worth $95,000. Cannon Global Investment Management LLC bought a new stake in shares of Indivior in the 1st quarter worth $95,000. New York State Common Retirement Fund bought a new stake in shares of Indivior in the 1st quarter worth $295,000. Finally, Y Intercept Hong Kong Ltd bought a new stake in shares of Indivior in the 1st quarter worth $207,000. Institutional investors own 60.33% of the company’s stock.

Indivior Price Performance

Shares of NASDAQ INDV opened at $23.17 on Friday. Indivior has a 12-month low of $7.33 and a 12-month high of $25.10. The stock’s 50 day simple moving average is $23.00 and its 200 day simple moving average is $15.99.

Indivior (NASDAQ:INDV) last announced its quarterly earnings results on Thursday, July 31st. The company reported $0.51 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.26 by $0.25. The business had revenue of $302.00 million for the quarter, compared to the consensus estimate of $239.43 million. Indivior had a negative return on equity of 86.28% and a net margin of 6.65%. Indivior has set its FY 2025 guidance at EPS. Sell-side analysts expect that Indivior will post 1.22 earnings per share for the current year.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.